Lukmed 2 Sp. z o.o.

The trials here

What the 33 trials at this site are about, from their registry records.

Conditions

• Obesity12 trials
• Type 2 diabetes7 trials
• Sjögren's disease5 trials
• Endometriosis2 trials
• Heart failure2 trials
• Psoriasis2 trials
• Psoriatic arthritis2 trials
• Rheumatoid arthritis2 trials
• Ulcerative colitis2 trials
• Atrial fibrillation1 trial
• Crohn's disease1 trial
• High blood pressure1 trial
• and 2 more

Phase

• Phase 325 trials
• Phase 28 trials

Status

• Active, not recruiting12 trials
• Completed10 trials
• Recruiting7 trials
• Not yet recruiting4 trials

Lead sponsor

• Boehringer Ingelheim4 trials
• Novo Nordisk A/S3 trials
• Ascletis Pharma (China) Co. Ltd.2 trials
• Janssen Research & Development, LLC2 trials
• Kailera2 trials
• and 18 more

Running trials

• Not yet recruiting

  Efficacy And Safety of Olatorepatide in Adults With Overweight or Obesity Without Diabetes

  NCT07896265· Phase 3· Regeneron Pharmaceuticals· Source

• Not yet recruiting

  A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity

  NCT07919405· Phase 3· Novo Nordisk A/S· Source

  Contact: Novo Nordisk

• Recruiting

  Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Weight-Related Comorbidities

  2026-526172-23-00· Phase 3· Ascletis Pharma (China) Co. Ltd.· Source

• Recruiting

  Efficacy and Safety of Once-Daily Oral ASC30 Compared with Placebo in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus

  2026-526336-39-00· Phase 3· Ascletis Pharma (China) Co. Ltd.· Source

• Recruiting

  A study of LY4268989 in participants with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

  2025-524404-29-00· Phase 2· Eli Lilly & Co.· Source

• Active, not recruiting

  AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight

  NCT07400107· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

  NCT07483073· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  NCT07351058· Phase 3· Hoffmann-La Roche· Source

• Not yet recruiting

  A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)

  2025-522471-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Recruiting

  Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease

  NCT07404865· Phase 3· Vor Biopharma· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

  NCT07400653· Phase 3· Pfizer· Source

• Active, not recruiting

  Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

  NCT07284901· Phase 3· Kailera· Source

• Active, not recruiting

  Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity

  NCT07311850· Phase 3· Pfizer· Source

• Active, not recruiting

  Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

  NCT07284875· Phase 3· Kailera· Source

• Active, not recruiting

  A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis

  NCT07260669· Phase 2· Gesynta Pharma AB· Source

• Active, not recruiting

  Trial of Sibeprenlimab in the Treatment of Sjögren’s Disease

  2024-516295-14-00· Phase 2· Otsuka Pharmaceutical Development & Commercialization Inc.· Source

• Active, not recruiting

  Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity

  NCT06979531· Phase 2· Immunovant Sciences GmbH· Source

• Recruiting

  A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart

  NCT06935370· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs

  2024-516213-20-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Active, not recruiting

  Nipocalimab in Moderate to Severe Sjogren's Disease

  NCT06741969· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

  NCT06625060· Phase 2· Ipsen· Source

• Recruiting

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

  NCT06424288· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Janssen Research & Development, LLC· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity5 recruiting
• Heart failure2 recruiting
• Type 2 diabetes2 recruiting
• Ulcerative colitis2 recruiting
• Crohn's disease1 recruiting
• High blood pressure1 recruiting
• Psoriatic arthritis1 recruiting
• Sjögren's disease1 recruiting

Closed trials

• Completed

  A Study of the Efficacy and Safety of Efgartigimod in Patients with Primary Sjögren's Syndrome (pSjD) (UNITY)

  NCT06684847· Phase 3· Argenx· Source

• Completed

  A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 [proposed etanercept biosimilar] to Enbrel® [EU-sourced] in rheumatoid arthritis

  2024-510826-16-00· Phase 3· Mabxience Research S.L.· Source

• Completed

  A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis

  2023-506664-14-00· Phase 3· Dr Reddy's Laboratories Limited· Source

• Completed

  A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 Diabetes

  NCT06542874· Phase 2· Novo Nordisk A/S· Source

• Completed

  A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with moderate to severe endometriosis-related pain

  2022-501310-57-00· Phase 2· Organon LLC· Source

• Completed

  Efficacy, safety, PK, PD, and immunogenicity of BP16 in post-menopausal osteoporosis

  2023-503790-37-00· Phase 3· Curateq Biologics Private Limited· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight

  NCT06066528· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

  NCT06066515· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

  NCT06108544· Phase 3· Takeda· Source

• Completed

  Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis

  NCT04036435· Phase 3· Bristol-Myers Squibb· Source